Tests engineered T cells against returning B cell cancers
Tests engineered immune cells targeting CD19 in B cell blood cancers.
Plain-language title generated from the registry record
Registry title: 4SCAR19U T Cells Targeting B Cell Malignancies
Key facts
- Where
- Shenzhen, ChinaSee the site
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with relapsed or hard-to-treat B cell cancers whose cells carry CD19. It tests a CAR T cell treatment called 4SCAR19U.
- Age
- From 6 Months to 75 Years
- Sex
- All sexes can join.
- Disease stage
- Relapsed or refractory B cell malignancies (the cancer came back or did not respond to treatment).
- Earlier treatment
- People with a prior failed CAR-T treatment cannot join. People on systemic steroid treatment within a week of the treatment cannot join.
- Biomarker or test result
- B cells must show CD19 on their surface.
Main reasons for not taking part
- Other active diseases that make it hard to judge the response to treatment
- Bacterial, fungal or viral infection that cannot be controlled
- Living with HIV
- Active HBV or HCV infection
- Pregnant and nursing mothers
Read by machine on 9 November 2026.
Where in China
- Shenzhen Geno-immune Medical InstituteShenzhen, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shenzhen Geno-Immune Medical Institute
- Trial code
- NCT05995015
- Record updated
- 30 October 2026
- Original description
The purpose of this study is to assess the feasibility, safety and efficacy of universal CAR T cell therapy against CD19-positive hematological malignancies using a novel CD19-specific CAR T cell product, 4SCAR19U T cells. The study also aims to learn more about the function of the 4SCAR19U T cells and their persistence in patients. This is a phase I trial enrolling patients from multiple clinical centers.Read full original descriptionShow less
Universal 4SCAR19U T Cell Therapy for the Treatment of Relapsed and Refractory B Cell Malignancies
The purpose of this study is to assess the feasibility, safety and efficacy of universal CAR T cell therapy against CD19-positive hematological malignancies using a novel CD19-specific CAR T cell product, 4SCAR19U T cells. The study also aims to learn more about the function of the 4SCAR19U T cells and their persistence in patients. This is a phase I trial enrolling patients from multiple clinical centers.
Inclusion: Age older than 6 months; Primary B cell surface expression of CD19; The KPS score over 80 points, and survival time is more than 1 month; Greater than Hgb 80 g/L; No contraindications to blood cell collection.
Exclusion: under systemic steroid treatment within a week of the treatment; Prior failed CAR-T treatment; Accompanied with other active diseases, and difficult to assess response after treatment; Bacterial, fungal, or viral infection, unable to control; Living with HIV; Active HBV or HCV infection; Pregnant and nursing mothers.